PDE3 Publications

  • A Phosphodiesterase 3B-based Signaling Complex Integrates Exchange Protein Activated by cAMP 1 and Phosphatidylinositol 3-Kinase Signals in Human Arterial Endothelial Cells. Wilson LS, Baillie GS, Pritchard LM, Umana B, Terrin A, Zaccolo M, Houslay MD, Maurice DH. J Biol Chem. 2011 May 6;286(18):16285-96.
  • Numerous distinct PKA-, or EPAC-based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4 coordination of cell adhesion. Raymond DR, Wilson LS, Carter RL, Maurice DH. Cell Signal. 2007 Dec;19(12):2507-18.
  • Both protein kinase A and exchange protein activated by cAMP coordinate adhesion of human vascular endothelial cells. Netherton SJ, Sutton JA, Wilson LS, Carter RL, Maurice DH. Circ Res. 2007 Oct 12;101(8):768-76.
  • PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Kerfant BG, Zhao D, Lorenzen-Schmidt I, Wilson LS, Cai S, Chen SR, Maurice DH, Backx PH. Circ Res. 2007 Aug 17;101(4):400-8.
  • Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation. Palmer D, Jimmo SL, Raymond DR, Wilson LS, Carter RL, Maurice DH. J Biol Chem. 2007 Mar 30;282(13):9411-9.
  • Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex. Elbatarny HS, Maurice DH. Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E695-702.
  • Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Tilley DG, Maurice DH. Mol Pharmacol. 2002 Sep;62(3):497-506.
  • Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Dunkerley HA, Tilley DG, Palmer D, Liu H, Jimmo SL, Maurice DH. Mol Pharmacol. 2002 May;61(5):1033-40
  • Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease. Netherton SJ, Jimmo SL, Palmer D, Tilley DG, Dunkerley HA, Raymond DR, Russell JC, Absher PM, Sage EH, Vernon RB, Maurice DH. Diabetes. 2002 Apr;51(4):1194-200.
  • Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Palmer D, Maurice DH. Mol Pharmacol. 2000 Aug;58(2):247-52.
  • Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Liu H, Maurice DH. Br J Pharmacol. 1998 Dec;125(7):1501-10.
  • Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Palmer D, Tsoi K, Maurice DH. Circ Res. 1998 May 4;82(8):852-61.
  • Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Rose RJ, Liu H, Palmer D, Maurice DH. Br J Pharmacol. 1997 Sep;122(2):233-40.
  • Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Maurice DH, Haslam RJ. Eur J Pharmacol. 1990 Dec 4;191(3):471-5.
  • Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Maurice DH, Haslam RJ. Mol Pharmacol. 1990 May;37(5):671-81.